RECRUITING

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

Conditions

Prediabetes Cystic Fibrosis (CF)Cystic Fibrosis-related Diabetes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.

Official Title

CGM Dynamic Index (CDI) for Predicting Prediabetes in People With Cystic Fibrosis

Quick Facts

Study Start:2025-06-15

Study Completion:2026-07-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06642610

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 55 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* CF individuals aged 12-55 years. * CF without diabetes or with prediabetes (as defined by OGTT and HbA1c). * Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection.	* Pregnancy. * History of transplant. * Use of immunosuppressant drugs. * Use of oral steroids or any medication known to interfere with glucose. * Allergy to adhesives. * Individuals with severe concurrent medical conditions that could confound glucose monitoring data (e.g., terminal illness, major organ failure). * Conditions that may make unsafe for participants to do study or impair or confound the study at the discretion of the investigator

Inclusion Criteria

Exclusion Criteria

* CF individuals aged 12-55 years.
* CF without diabetes or with prediabetes (as defined by OGTT and HbA1c).
* Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection.

* Pregnancy.
* History of transplant.
* Use of immunosuppressant drugs.
* Use of oral steroids or any medication known to interfere with glucose.
* Allergy to adhesives.
* Individuals with severe concurrent medical conditions that could confound glucose monitoring data (e.g., terminal illness, major organ failure).
* Conditions that may make unsafe for participants to do study or impair or confound the study at the discretion of the investigator

Contacts and Locations

Study Contact

Eslam Montaser, PhD

CONTACT

4344660570

emontase@iu.edu

Study Locations (Sites)

Indiana University Health, University Hospital

Indianapolis, Indiana, 46202

United States

Collaborators and Investigators

Sponsor: Indiana University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-15

Study Completion Date2026-07-30

Study Record Updates

Study Start Date2025-06-15

Study Completion Date2026-07-30

Terms related to this study

Additional Relevant MeSH Terms

Prediabetes
Cystic Fibrosis (CF)
Cystic Fibrosis-related Diabetes